S100A4 and brain neoplasm: Furthermore, an increase of S100A4 release in biological fluids was observed in different types of cancers such as brain tumors, breast, colon and lung carcinomas, demonstrating a possible exploitation of S100A4 as a prognostic biomarker to detect early stage tumors and as a marker to evaluate metastatic events [9].